MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'investments'. Sat, 03 Sep 2011 02:11:52 +0100 http://www.medworm.com/index.php?rid=4040617&cid=t_151733_109_f&fid=34761&url=http%3A%2F%2Ffeeds.feedblitz.com%2F%7E%2F21224594%2F0%2Fneuromarketing%7EScary-Thought-A-Treatment-for-Impulse-Buying.htm Here’s a thought that would terrify many marketers… what if consumers prone to impulsive behavior decided to take a pill to quiet those impulses? While clearly lack of impulse control is a serious issue for some individuals and can lead to extreme behavior, marketers of everything from checkout lane mints to Porsches depend to some [...] CommentsThis will have to happen: - These self-harming behaviors are ... by Rich and Co.Ramon, I agree that the world would certainly be a different ... by Roger DooleyI think in the long run it will be better for us humans. ... by RamonRelated StoriesBit Pickles & Fuzzy OlivesPaper Beats Digital For EmotionNeuromarketing Standards Battle Ahead? (Source: Neuromarketing) Neuromarketing blogs http://www.medworm.com/rss/comments.php?id=4040617 Thu, 07 Oct 2010 12:43:14 +0100 4040617 http://www.medworm.com/index.php?rid=3729846&cid=t_151733_87_f&fid=36050&url=http%3A%2F%2Fblisstree.com%2Flive%2Fwhats-in-your-wallet-learnvest-ceo-alexa-von-tobel-shows-the-contents-of-her-money-bag%2F Keeping track of your cash, coins, and credit cards seems like something you should learn how to do in high school, but some of us still haven’t mastered the art of organizing our wallets. If you ever find yourself digging through crumpled receipts or wishing you hadn’t left certain cards at home, check out these tips from LearnVest. (And check out LearnVest’s original post for more details and a peek into Learnvest CEO Alexa von Tobel’s personal wallet.) What to keep in your wallet: Credit Card – LearnVest suggests having two credit cards in your name: One for regular use, another for emergency use only. Keep the emergency card tucked away at home, and keep the other in your wallet at all times. Cash – The key here is not too much, not too little. Between $25... Breastfeeding 1-2-3 blogs http://www.medworm.com/rss/comments.php?id=3729846 Tue, 06 Jul 2010 18:22:14 +0100 3729846 http://www.medworm.com/index.php?rid=3552586&cid=t_151733_180_f&fid=38612&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2Fpickthebrain%2FLYVv%2F%7E3%2FK07yTmNSAtg%2F It’s common to want to look the other way when we’re faced with dealing with our finances. It’s not a very exciting task for most people. And some people are outright scared to look at their finances, afraid they’ll discover a mess. But today I want to challenge you to dive right in there and make some progress. To give you a bit of guidance and to lessen the stress of this challenge, I’ve provided some steps you can take today that will quickly help to improve your finances. Here are the Top 10 Ways to Improve Your Bottom Line: 1. Discover Your Personal Net Worth: Major corporations are judged by their financial ratios. One of the most important is their net worth (assets minus debts). Take a moment to calculate your own net worth. Subtract all your debts (mo... PickTheBrain | Motivation and Self Improvement blogs http://www.medworm.com/rss/comments.php?id=3552586 Tue, 11 May 2010 06:56:28 +0100 3552586 http://www.medworm.com/index.php?rid=3283515&cid=t_151733_87_f&fid=36438&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2Fy93MnVvdGE0%2F By Tad DeHavenThe same federal agency that brought us monumental failures like public housing wants to play a bigger role in fostering so-called regional “smart growth.” HUD secretary Shaun Donovan recently traveled to Portland, Oregon to announce the Obama administration’s new Office of Sustainable Housing and Communities. This new bureaucracy will distribute $140 million in grants for regional “smart growth” planning: With OSHC’s grant programs, HUD will provide funding to a wide variety of multi-jurisdictional and multi-sector partnerships and consortia, from Metropolitan Planning Organizations and State governments, to non-profit and philanthropic organizations. These grants will be designed to encourage regions to build their capacity to integrate economic development, lan... Cato-at-liberty blogs http://www.medworm.com/rss/comments.php?id=3283515 Thu, 18 Feb 2010 13:50:35 +0100 3283515 http://www.medworm.com/index.php?rid=3145957&cid=t_151733_87_f&fid=36438&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FZwijLskzamc%2F By Chris EdwardsToday, Cato released a report on employee compensation in state and local governments. As states struggle to balance their budgets in coming months, they should look to find savings in employee compensation, which represents half of all state and local spending. The particular issue of excessive state pensions is being probed by newspapers across the nation. Over at Reason, Nick Gillespie discusses the problem in his home state of Ohio. That state’s newspapers teamed up to pen a series of articles on government pensions, which are representative of the growing pension problems in many states. There has been a parallel series of articles across the nation on “pay-to-play” state pension scandals. These scandals involve Wall Street firms bribing pub... Cato-at-liberty blogs http://www.medworm.com/rss/comments.php?id=3145957 Tue, 05 Jan 2010 19:15:39 +0100 3145957 http://www.medworm.com/index.php?rid=3052423&cid=t_151733_180_f&fid=38610&url=http%3A%2F%2Fwww.productivity501.com%2F10-stages-of-financial-freedom%2F349%2F 0. You Earn Less than you Spend This is obviously a good place to avoid and represents the least amount of freedom.  No one should be here, but I added it because I know many people (particularly in the US) operate regularly in this stage. 1. Your Job Covers Your Expenses This is where a lot of people are.  You spend everything you make.  At this stage, losing your job is a terrifying prospect because you are only a week or two away from being back in stage 0.  A few more weeks, (depending on how long you can string out your credit cards) and you’d be looking at bankruptcy.  At this stage, changing jobs is very risky because, if it doesn’t work out, you have very little cushion to let you find another job. 2. Your Job Covers Your Expenses and Savings Once your expenses ar... Productivity501 blogs http://www.medworm.com/rss/comments.php?id=3052423 Wed, 02 Dec 2009 18:00:55 +0100 3052423 http://www.medworm.com/index.php?rid=1713852&cid=t_151733_125_f&fid=34820&url=http%3A%2F%2Fwww.dentalblogs.com%2Farchives%2Fadministrator%2Fon-target-an-exclusive-dentalblogs-interview-with-keith-drayer-of-henry-schein-financial-services%2F 8/18/08 - The information you need, when you need it. That’s what DentalBlogs is all about. And with the economy facing hard hits recently, expert financial information is just what the dentist ordered. Keith Drayer, Vice President at Henry Schein Financial Services, kindly agreed to provide some timely and valuable insight for our DentalBlogs readers. On Practice Transitions DB: In this tumultuous economy, dentists are worried about their retirement. What advice would you give those preparing for retirement in the next few years? KD: Think of it in terms of selling a home. Some people prepare to sell their house by fixing up their homes to be their dream house, only to sell it soon after. Then the buyer gets a spectacular home. It’s a shame that the seller didn’t get to en... dental blog for dentists about dentistry blogs http://www.medworm.com/rss/comments.php?id=1713852 Mon, 18 Aug 2008 14:59:22 +0100 1713852 http://www.medworm.com/index.php?rid=1332722&cid=t_151733_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F259632331%2F Anyone familiar with involuntary emotional expression disorder? This is another way of saying uncontrollable laughing or crying, and a little drugmaker called Avanir Pharmaceuticals hopes to market a pill for this “distinct neurological disorder.” Also known as pseudobulbar affect, the affliction has gotten talked up in recent years and investors are buying into the concept. Earlier this week, Avanir received commitments for $40 million in funding from a group of venture capital firms, including ProQuest Investments, whose scientific advisors include Howard Scher, a noted oncologist caught up in the conflicts-of-interest scandal engulfing the FDA over the Provenge prostate-cancer vaccine. The proceeds will be used to complete a Phase III test of its Zenvia pill, which used to b... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1332722 Fri, 28 Mar 2008 14:49:44 +0100 1332722 http://www.medworm.com/index.php?rid=1212312&cid=t_151733_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F230530447%2F After taking a $275 million charge for investing in sub-prime securities, which contributed to a loss in the fourth quarter, ceo Jim Cornelius is now out recruiting. “I’m a big believer in accountability, and we’re looking for a new corporate treasurer and a couple of people under him,” the ceo told Merrill Lynch conference in New York, according to Dow Jones. Cornelius called the soured investments “an absolute surprise.” He conceded that “had I been smart enough to ask about that in detail in the fourth quarter, I’m not sure we would have avoided the loss completely, but maybe we would have minimized it.” Cornelius didn’t identify the corporate treasurer. A Bristol-Myers spokeswoman writes us to say that “We have an interi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1212312 Wed, 06 Feb 2008 21:01:46 +0100 1212312 http://www.medworm.com/index.php?rid=1124944&cid=t_151733_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F209900167%2F You may recall that last month, three congressmen wrote the House Energy and Commerce Committee to ask for a hearing into allegations that undislosed financial conflicts of interest among FDA advisory committee members may have swayed an agency decision last spring to delay approval of Provenge, a prostate cancer vaccine being developed by Dendreon. The move capped several months of controversy over the role of the panel members, in particular, Howard Scher, an oncologist at Sloan-Kettering Memorial Cancer Center in New York. Scher was one of two FDA panel members who wrote the agency urging a go-slow approach. It so happens, that Scher also serves on the scientific advisory board of ProQuest Investments, a venture capital firm that invested in Novacea, which is developing a rival cancer m... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1124944 Wed, 02 Jan 2008 13:48:39 +0100 1124944 http://www.medworm.com/index.php?rid=1005357&cid=t_151733_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F180186632%2F A little company called Novacea is making big news today. A late-stage trial of its prostate-cancer medication was halted after one of arm of the study containing the drug showed a higher death rate compared with standard care. The disclosure, which you can see in the Novacea statement, sent Novacea stock tumbling so far by as much as 63 percent. The main goal of the study was to compare the benefits of a weekly dose of Asentar in combination with Taxotere, the Sanofi-Aventis cancer drug, to the current standard of care in the treatment of androgen-independent prostate cancer (AIPC). But enrollment was suspended in other trials in other indications until data is reviewed. So far, more than 900 of the 1,200 needed patients were enrolled in the study. The news, as always, reverberates in dif... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1005357 Mon, 05 Nov 2007 19:26:25 +0100 1005357 http://www.medworm.com/index.php?rid=947373&cid=t_151733_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F169035743%2Fmoodys_lowers_pharmas_outlook_1.html Wednesday Moody's Investor Services downgrades the pharmaceutical sector's outlook from "stable" to "Negative" for the next twelve months.Citing a tough regulatory climate, lagging pipelines and upcoming patent expirations, Moody's senior vice president and credit analyst noted that large pharma companies have been buying up biotech companies and making more developments deals to try and compensate for lagging research and development.Merck's (NYSE:MRK) buyout of biotech firm Sirna Therapeutics for the price of $1.1 billion and Abbott Laboratories' (NYSE:ABT) $3.7 billion takeover of Kos Pharmaceuticals are just two examples of large acquisitions over the last year. Pfizer Inc. ( NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY) have ... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=947373 Fri, 12 Oct 2007 17:43:40 +0100 947373 http://www.medworm.com/index.php?rid=938932&cid=t_151733_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F167488804%2F This is one way to play connect the dots in the Provenge controversy. Before we explain, let us remind you that Provenge is the prostate-cancer vaccine that was recommended last spring by an FDA panel, but later put on hold after the agency received letters from two panel members urging a go-slow approach. The delay set off a firestorm - the two docs received threats amid allegations of conflicts of interest; and patients and investors in Dendreon, which is developing the vaccine, filed a lawsuit against the FDA, charging agency political intrigue was also involved. And so it comes to our attention that FDA commish Andy von Eschenbach - who is named in the lawsuit and held responsible by cancer patients for the Provenge delay - has a link, of sorts, to Howard Scher, a prominent oncologist ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=938932 Tue, 09 Oct 2007 15:43:24 +0100 938932 http://www.medworm.com/index.php?rid=509318&cid=t_151733_87_f&fid=34867&url=http%3A%2F%2Fwww.thediabetesblog.com%2F2007%2F03%2F29%2Faccidental-diabetes-drug%2F Filed under: Type 2, Adult Onset, Drugs, ResearchMuch like a roadblock, but with a fortuitous outcome -- an experimental heart drug didn't achieve the primary goal of a late-stage trial but it did dramatically reduce the risk patients would develop diabetes. The anti-oxidant, anti-inflammatory drug, the first of its kind, reduced the risk of developing diabetes by 64% and demonstrated a small but statistically significant reduction in blood sugar after 12 months. The study included data from 6,144-patients. The company believes this finding to be a serendipitous outcome, despite the initial shortcomings of the trial objective. They need to confirm it in a large clinical trial. The impressive diabetes results may come as a surprise to investors who have abandoned AtheroGenics or who have b... The Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=509318 Thu, 29 Mar 2007 04:00:00 +0100 509318